Aug, 12 2022

Genentech, Inc., Eli Lilly and Company and Merck & Co., Inc. are dominating the Argentina Gastric Cancer Treatment Market in 2020

Argentina Gastric Cancer Treatment Market is expected to grow with the CAGR of 9.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/argentina-gastric-cancer-treatment-market

Argentina gastric cancer treatment market is a highly consolidated market. The market has witnessed increased strategic developments owing to favorable market scenario.

The major players dealing in Argentina gastric cancer treatment market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market

Genentech, Inc. is dominating player in Argentina gastric cancer treatment market. The other key players existing in the market includes Novartis AG, Pfizer Inc., Eli Lilly and Company., Genentech Inc., Teva Pharmaceutical Industries Ltd., Merck & co., Inc., AstraZeneca, Bristol_ Myers Squibb Company, Eriochem SA., Laboratories IMA, Biotoscana group, Tuteur Argentina, and Celnova pharma among others.

Genentech, Inc. (a subsidiary of a subsidiary of F. Hoffmann-la Roche)

Genentech, Inc. was founded in 1976 and is headquartered in California, U.S. The company focuses on pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. The company offers range of product categories including Medicines & Products and Pipeline in which market focused category is Our Medicines & Products.

In September 2021, Genentech presented data from industry-leading portfolio at esmo 2021 showing significant progress in early stage and uncommon cancers. This conference helped the company showcase its product portfolio in the conference which helped led to increased sales in the forecasted period.

The company has global presence in North-America.

Eli Lilly and Company

Eli Lilly and Company was founded in 1876 and is headquartered in Indiana, U.S. The company is engaged in production and trading of high quality medicines for which comes under the human pharmaceutical products. The company offers range of product categories such as Historic Medicines, Current Medicines in which market focused category is Current Medicines.

In May 2020, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers. This new drug approval of the company has increased its sales and demand in the market leading to increased sales in the future.

The company has global presence in North America, Asia Pacific, South America, Europe, Latin America. The company has many subsidiaries such as Alnara Pharmaceuticals, Inc. (U.S.), AME Torreview LLC (U.S.), Andean Technical Operations Center (Peru), Dista-Produtos Quimicos & Farmaceuticos, LDA (Portugal) and E L Management LLC (U.S.) among others

Merck & Co., Inc.

Merck & Co., Inc. was founded in 1891 and is headquartered in Germany, Europe. The main focus of the company is that it delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It has following business segments such as Pharmaceuticals and Animal health segment. The market focused segment is Pharmaceuticals .The company offers product categories including Oncology, Vaccine, Hospital Acute Care, Immunology, Neuroscience, Virology, Cardiovascular, Diabetes, women's health in which the market focused category falls under Oncology.

For instance,

In June 2020, Merck’s KEYTRUDA (pembrolizumab) approved in China for second-line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma with tumors express PD-L1 (CPS ≥10).This helped the company to increase its product portfolio.

The company has global presence in the America, the Middle East, Africa, Eastern Europe and Asia Pacific. The company has many subsidiaries such as Abmaxis Inc., (Europe), Afferent Pharmaceuticals.Inc., (Europe), Aleis Pty Ltd (Europe), , Allflex (Argentina) , S.A.S. (France) ,Allflex Group (Europe), ,Allflex Private Limited (Europe) among others.

CHOOSE LICENCE TYPE

Enterprise User 7000
Single User 4800
DBMR Factbook 3000
DBMR Prime 8000
DBMR Supreme 12000

Buy Now

Advance Formative Research Customization Request for bulk Reports

Latest Press Release

Growth in Offshore Oil and Gas Activities is driving the Growth of the U.S Ship Repair and Maintenance Services Market

Rising Prevalence of Genetic Disorders is Driving the Growth of the Global Multiple Hereditary Exostosis Market

Growing Industrialization Fuels Lubricant Usage in Machinery and Equipment is Expected to Drive the Growth for the U.S. Lubricants Market

Rising Demand for Quality Control is Driving the Growth of the Global Industrial Metrology Market

Increasing Prevalence Of Hepatitis B Infections Drives the Growth of Global Hepatitis B Treatment Market

VIEW ALL

Client Testimonials

David Manning - Thermo Fisher Scientific

Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Manager - Market Analytics,

Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,

(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Business Intelligence and Analytics,

Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst,

Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director,

Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,

A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director,

Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager,

Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations,

GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst,

Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager,

Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment

MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer

Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro

Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)

UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future

Press Release